Context Therapeutics Inc (CNTX) - Total Liabilities
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has total liabilities worth $6.06 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CNTX operating cash flow to assess how effectively this company generates cash.
Context Therapeutics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Context Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Context Therapeutics Inc (CNTX) shareholders funds for net asset value and shareholders' equity analysis.
Context Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Context Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AIRA Capital Public Company Limited
BK:AIRA
|
Thailand | ฿5.32 Billion |
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
China | CN¥510.98 Million |
|
EMS Limited
NSE:EMSLIMITED
|
India | Rs2.74 Billion |
|
Huons Co. Ltd
KQ:243070
|
Korea | ₩248.98 Billion |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
Malaysia | RM317.06 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $61.76 Million |
|
Atrium Therapeutics, Inc. Common Stock
NASDAQ:RNA
|
USA | $71.07 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Context Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Context Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Context Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Context Therapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Context Therapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.86 Million | -31.76% |
| 2023-12-31 | $4.19 Million | +30.68% |
| 2022-12-31 | $3.21 Million | +5.74% |
| 2021-12-31 | $3.03 Million | -82.55% |
| 2020-12-31 | $17.39 Million | -28.25% |
| 2019-12-31 | $24.23 Million | +158.22% |
| 2017-12-31 | $9.38 Million | -13.83% |
| 2016-12-31 | $10.89 Million | -- |
About Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more